Pfizer India (PFIZER) Q1 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 24/25 earnings summary
2 Sep, 2025Executive summary
Unaudited financial results for the quarter ended June 30, 2024, were approved by the Board on July 29, 2024.
Results prepared in accordance with Ind AS and SEBI regulations.
Financial highlights
Revenue from operations for Q1 FY25 was ₹562.86 crore, up from ₹531.36 crore in Q1 FY24.
Total income for the quarter was ₹604.70 crore, compared to ₹564.82 crore in the same quarter last year.
Net profit for the quarter was ₹150.71 crore, up from ₹93.53 crore year-over-year.
Earnings per share (EPS) for the quarter stood at ₹32.94, compared to ₹20.44 in Q1 FY24.
Profit before tax was ₹202.62 crore, up from ₹125.75 crore in the same quarter last year.
Key financial ratios and metrics
Gross margin improved as total expenses were ₹402.08 crore versus ₹439.07 crore in Q1 FY24.
EPS before exceptional items was ₹32.94 for the quarter.
Latest events from Pfizer India
- Revenue and profit declined due to recalls and price controls, but key brands and new launches drove growth.PFIZER
Q4 23/24 - Q1 FY27 saw higher revenue and profit, with EPS up and strong equity despite exceptional costs.PFIZERQ1 26/27
- FY26 revenue rose, net profit reached ₹722.43 crore, and a ₹75/share dividend is proposed.PFIZERQ4 25/26
- Net profit increased to ₹189.02 crore in Q3 FY26, with stable revenue and notable exceptional costs.PFIZERQ3 25/26
- Strong revenue and profit growth, with major dividends paid after asset sale gains.PFIZERQ2 25/26
- Strong financials, special dividend, and new launches mark a milestone 75th year.PFIZERAGM 2025
- Despite a tough year, strong brand growth and new launches signal a return to positive momentum.PFIZERAGM 2024
- Revenue and profit rose year-over-year, with strong operations and pending asset sale.PFIZERQ2 24/25
- Revenue and profit increased year-over-year, with Thane property sale awaiting approval.PFIZERQ3 24/25